Publications
Detailed Information
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, K. -W. | - |
dc.contributor.author | Park, S. R. | - |
dc.contributor.author | Oh, D. -Y. | - |
dc.contributor.author | Park, Y. -I. | - |
dc.contributor.author | Khosravan, R. | - |
dc.contributor.author | Lin, X. | - |
dc.contributor.author | Lee, S. -Y. | - |
dc.contributor.author | Roh, E. -J. | - |
dc.contributor.author | Valota, O. | - |
dc.contributor.author | Lechuga, M. J. | - |
dc.contributor.author | Bang, Y. -J. | - |
dc.date.accessioned | 2021-01-31T11:55:20Z | - |
dc.date.available | 2021-01-31T11:55:20Z | - |
dc.date.created | 2020-12-21 | - |
dc.date.issued | 2013-12 | - |
dc.identifier.citation | Investigational New Drugs, Vol.31 No.6, pp.1547-1558 | - |
dc.identifier.issn | 0167-6997 | - |
dc.identifier.other | 119335 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173136 | - |
dc.description.abstract | Background We evaluated the maximum tolerated dose (MTD) and safety of sunitinib plus capecitabine/cisplatin (XP) or capecitabine/oxaliplatin (XELOX) in Korean patients with advanced gastric cancer (GC). Methods Sunitinib (37.5 or 25 mg/day) was administered on a 2-week-on/1-week-off schedule with chemotherapy. Assessments included dose-limiting toxicity (DLT), safety, pharmacokinetics, and antitumor activity. Results Twenty-eight patients received sunitinib/XP; 48 received sunitinib/XELOX. The MTDs were: sunitinib 25 mg/day, cisplatin 80 mg/m(2), and capecitabine 1,000 mg/m(2); sunitinib 37.5 mg/day, oxaliplatin 110 mg/m(2), and capecitabine 800 mg/m(2); and sunitinib 25 mg/day, oxaliplatin 110 mg/m(2), and capecitabine 1,000 mg/m(2). DLTs at the MTDs comprised grade (G) 4 febrile neutropenia plus G3 diarrhea (n = 1; sunitinib/XP), dose delays due to hematologic toxicity (n = 2; both sunitinib/XP), G3 bleeding (menorrhagia; n = 1; sunitinib/XELOX), and G3 increased alanine aminotransferase levels (n = 1; sunitinib/XELOX). There was a high frequency of G3/4 hematologic adverse events observed with both treatment regimens, particularly with sunitinib/XP. Frequent non-hematologic, G3/4 adverse events were nausea, stomatitis, and hypophosphatemia with sunitinib/XP and hypophosphatemia and pulmonary embolism with sunitinib/XELOX. No drug-drug interactions were apparent. At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7 % and 43.5-45.5 % for sunitinib/XP and sunitinib/XELOX, respectively. Conclusions At the MTD, sunitinib/XELOX had an acceptable safety profile in patients with advanced GC. | - |
dc.language | 영어 | - |
dc.publisher | Kluwer Academic Publishers | - |
dc.title | Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1007/s10637-013-0032-y | - |
dc.citation.journaltitle | Investigational New Drugs | - |
dc.identifier.wosid | 000326602500016 | - |
dc.identifier.scopusid | 2-s2.0-84888588300 | - |
dc.citation.endpage | 1558 | - |
dc.citation.number | 6 | - |
dc.citation.startpage | 1547 | - |
dc.citation.volume | 31 | - |
dc.identifier.sci | 000326602500016 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Bang, Y. -J. | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | OXALIPLATIN | - |
dc.subject.keywordPlus | RECEPTORS | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | SU11248 | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordAuthor | Advanced gastric cancer | - |
dc.subject.keywordAuthor | Capecitabine | - |
dc.subject.keywordAuthor | Cisplatin | - |
dc.subject.keywordAuthor | Oxaliplatin | - |
dc.subject.keywordAuthor | Phase I | - |
dc.subject.keywordAuthor | Sunitinib | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.